Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Richardson, Paul [1 ]
Sandhu, Irwindeep [2 ]
Oriol, Albert [3 ,4 ]
Raab, Marc S. [5 ]
White, Darrell [6 ,7 ]
LeBlanc, Richard [8 ]
Perrot, Aurore [9 ]
Ocio, Enrique [10 ]
Raje, Noopur [11 ]
Hansen, Charlotte Toftmann [12 ]
Zhou, Zehua [13 ]
Civardi, Tiziana [14 ]
Ghiddi, Alessandro [14 ]
Katz, Jessica [13 ]
Peluso, Teresa [14 ]
Dimopoulos, Meletios A. [15 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Alberta, Edmonton, AB, Canada
[3] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
[4] Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain
[5] Univ Klinikum Heidelberg, Heidelberg, Germany
[6] Dalhousie Univ, Halifax, NS, Canada
[7] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[8] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada
[9] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[10] Hosp Univ Marques de Valdecilla IDIVAL, Santander, Spain
[11] Massachusetts Gen Canc Ctr, Boston, MA USA
[12] Odense Univ Hosp, Odense, Denmark
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Celgene Int Sarl, Boudry, Switzerland
[15] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Hematol & Med Oncol, Athens, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-053
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [1] Mezigdomide (MEZI; CC-92480) in Combination with Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Raab, M. S.
    Richardson, P. G.
    Sandhu, I
    Oriol, A.
    White, D.
    LeBlanc, R.
    Perrot, A.
    Ocio, E. M.
    Raje, N.
    Hansen, C. Toftmann
    Zhou, Z.
    Civardi, T.
    Katz, J.
    Peluso, T.
    Dimopoulos, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 56 - 56
  • [2] Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial
    Oriol, Albert
    Sandhu, Irwindeep
    Raab, Marc
    White, Darrell
    LeBlanc, Richard
    Raje, Noopur
    Ocio, Enrique
    Perrot, Aurore
    Facon, Thierry
    Rodriguez, Cesar
    Waesch, Ralph
    Amatangelo, Michael
    Zhou, Zehua
    Wang, Yue
    Civardi, Tiziana
    Koo, Philip
    Maciag, Paulo
    Zhu, Daniel
    Katz, Jessica
    Richardson, Paul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S31 - S31
  • [3] Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial
    Raab, Marc S.
    Oriol, Albert
    Sandhu, Irwindeep
    White, Darrell
    Leblanc, Richard
    Raje, Noopur
    Ocio, Enrique M.
    Perrot, Aurore
    Facon, Thierry
    Rodriguez, Cesar
    Waesch, Ralph
    Amatangelo, Michael
    Zhou, Zehua
    Wang, Yue
    Civardi, Tiziana
    Koo, Phillip
    Maciag, Paulo
    Zhu, Daniell
    Katz, Jessica
    Richardson, Paul G.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 115 - 115
  • [4] Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial
    Oriol, Albert
    Sandhu, Irwindeep
    Raab, Marc S.
    White, Darrell
    LeBlanc, Richard
    Raje, Noopur
    Ocio, Enrique M.
    Perrot, Aurore
    Facon, Thierry
    Rodriguez, Cesar
    Waesch, Ralph
    Amatangelo, Michael
    Zhou, Zehua
    Wang, Yue
    Civardi, Tiziana
    Koo, Phillip
    Maciag, Paulo
    Zhu, Daniel
    Katz, Jessica
    Richardson, Paul G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S566 - S566
  • [5] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Lonial, Sagar
    Richardson, Paul G.
    Popat, Rakesh
    Stadtmauer, Edward A.
    Larsen, Jeremy T.
    Oriol, A.
    Knop, Stefan
    Jagannath, Sundar
    Cook, Gordon
    Badros, Ashraf Z.
    Rodriguez-Otero, Paula
    Siegel, David S.
    Nguyen, Tuong Vi
    Di Micco, Antonia
    Amin, Alpesh
    Chen, Min
    Kueenburg, Elisabeth
    van de Donk, Niels W. C. J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S9 - S9
  • [6] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Knop, Stefan
    Lonial, Sagar
    Richardson, Paul
    Popat, Rakesh
    Stadtmauer, Edward A.
    Larsen, Jeremy T.
    Oriol, Albert
    Jagannath, Sundar
    Cook, Gordon
    Badros, Ashraf Z.
    Rodriguez-Otero, Paula
    Siegel, David
    Nguyen, Tuong Vi
    Di Micco, Antonia
    Amin, Alpesh
    Chen, Min
    Kueenburg, Elisabeth
    Van De Donk, Niels W. C. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 171 - 171
  • [7] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients with relapsed/refractory multiple myeloma (RRMM)
    Weisel, K.
    Knop, S.
    Lonial, S.
    Richardson, P. G.
    Popat, R.
    Stadtmauer, E. A.
    Larsen, J. T.
    Oriol, A.
    Jagannath, S.
    Cook, G.
    Badros, A. Z.
    Otero, Rodriguez P.
    Siegel, D. S.
    Nguyen, T., V
    Di Micco, A.
    Amin, A.
    Chen, M.
    Kueenburg, E.
    van de Donk, N. W. C. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 86 - 87
  • [8] Initial results of phase 1/2 study CC-92480-MM-002 onCELMoD CC-92480 in combination with bortezomib (BORT)and dexamethasone (DEX) in patients with relapsed /refractory multiple myeloma (RRMM)
    Raab, M. -S.
    Richardson, P. G.
    Ocio, E. M.
    Raje, N.
    Gregory, T.
    White, D.
    Oriol, A.
    Sandhu, I.
    LeBlanc, R.
    Rodriguez Valdes, C.
    Trudel, S.
    Waesch, R.
    Perrot, A.
    Bahlis, N. J.
    Zhou, Z.
    Lamba, M.
    Amatangelo, M.
    Civardi, T.
    Katz, J.
    Maciag, P.
    Peluso, T.
    Dimopoulos, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 86 - 86
  • [9] Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial
    Richardson, Paul G.
    Sandhu, Irwindeep
    Hofmeister, Craig C.
    Orlowski, Robert Z.
    White, Darrell
    Belotti, Angelo
    Hansen, Charlotte Toftmann
    Raje, Noopur S.
    Chow, Tracy T.
    Zhou, Zehua
    Civardi, Tiziana
    Koo, Phillip
    Zhu, Yue
    Katz, Jessica
    Oriol, Albert
    BLOOD, 2023, 142
  • [10] CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002
    Richardson, Paul G.
    Ocio, Enrique
    Raje, Noopur S.
    Gregory, Tara
    White, Darrell
    Oriol, Albert
    Sandhu, Irwindeep
    Raab, Marc-Steffen
    Le Blanc, Richard
    Rodriguez, Cesar
    Trudel, Suzanne
    Waesch, Ralph
    Perrot, Aurore
    Bahlis, Nizar J.
    Zhou, Zehua
    Lamba, Manisha
    Amatangelo, Michael
    Civardi, Tiziana
    Katz, Jessica
    Aciag, Paulo M.
    Peluso, Teresa
    Dimopoulos, Meletios A.
    BLOOD, 2021, 138
12345